Vagus nerve control of HMGB1 accessibility: a bioelectronic strategy for inflammation and pain Authors: Huan Yang, Michael Brines, Ulf Andersson Published: 2026 ABSTRACT AbstractHigh mobility group box 1 protein (HMGB1) is a central mediator of inflammation and pain, but efforts to neutralize it therapeutically have had limited clinical success. This gap suggests that the essential problem is not simply the abundance of extracellular HMGB1, but its accessibility: its availability to assemble into pathogenic complexes, engage receptors such as the receptor for advanced glycation end products (RAGE), enter cells, and deliver inflammatory cargo to the cytosol. Here, a perspective is advanced that integrates HMGB1 biology with the inflammatory reflex and the cholinergic anti-inflammatory pathway. In this framework, HMGB1 promotes inflammatory entry and amplification, whereas acetylcholine, acting through the vagus nerve and alpha7 nicotinic acetylcholine receptors, limits HMGB1 release and uptake of HMGB1-containing complexes. Vagus nerve stimulation therefore emerges as a bioelectronic strategy to restrict upstream access of danger signals to intracellular inflammatory pathways, in addition to suppressing downstream cytokine signaling. This formulation does not alter the established biology of HMGB1; rather, it places existing observations into a unifying model with direct relevance to inflammation and pain.Keywords: HMGB1, RAGE, Vagus nerve stimulation, Inflammatory reflex, Alpha7 nicotinic acetylcholine receptors, Acetylcholine, Inflammasome, Lysosome, Inflammation, Pain, Macrophage, Nociceptor Background The inflammatory reflex is a neural circuit that detects inflammatory signals and transmits efferent vagus nerve activity to restrain cytokine production and tissue injury (Tracey 2002; Chavan et al. 2017). The cholinergic anti-inflammatory pathway is a mechanistic arm of this reflex in which acetylcholine signaling through alpha7 nicotinic acetylcholine receptors (α7nAChR) limits innate immune activation (Tracey 2007; Rosas-Ballina et al. 2011). This framework has provided a foundation for bioelectronic medicine and for the development of vagus nerve stimulation as a strategy to control inflammation. HMGB1 is a highly conserved nuclear protein present in nearly all cells (Goodwin et al. 1973; Tang et al. 2023). Inside the cell, HMGB1 participates in chromatin organization and transcriptional regulation. Outside the cell, HMGB1 functions as an alarmin released by activated, stressed, or dying cells and drives inflammatory responses through receptors including RAGE, TLR4, and additional cell receptors (Tang et al. 2023; Wang et al. 1999; Scaffidi et al. 2002; Yang et al. 2010; Schiraldi et al. 2012; Rauvala and Rouhiainen 2007; LeBlanc et al. 2014; Andersson et al. 2000). HMGB1 also contributes to nociception and persistent pain (Yang et al. 2021; Agalave and Svensson 2015; Wan et al. 2016) in inflammatory settings (Yang et al. 2021). Despite extensive preclinical evidence implicating HMGB1 in sepsis, arthritis, ischemia–reperfusion injury, neuropathic pain, and other disorders, therapeutic strategies designed to bind or neutralize extracellular HMGB1 have not yet delivered broad clinical benefit (Tang et al. 2023; Yang et al. 2020). That experience raises a more precise mechanistic question: are current strategies aimed at the right variable? A persuasive interpretation of the available evidence is that pathogenic HMGB1 biology depends less on how much HMGB1 is present than on whether it is accessible to form complexes, traffic through receptor-mediated uptake pathways, and deliver inflammatory cargo into cells. Accumulating evidence indicates that HMGB1 binds damage- and pathogen-associated molecular patterns (DAMPs and PAMPs) and facilitates their cellular uptake via receptors such as RAGE (Tang et al. 2023; Tian et al. 2007; Ivanov et al. 2007; Yanai et al. 2009; Porat et al. 2018; Ghitti et al. 2025; Ferhani et al. 2010; Sha et al. 2008; Liu et al. 2014, 2019; Deng et al. 2018; Chang et al. 2024; Jung et al. 2025; Bertheloot et al. 2016), which subsequently promotes lysosomal destabilization and inflammasome activation following endocytosis (Deng et al. 2018; Xu et al. 2014; Hu et al. 2025; Alu et al. 2020). Notably, HMGB1 contains two distinct RAGE-binding sites, whereas interactions with other cognate receptors appear to involve only a single binding interface (Rauvala and Rouhiainen 2007; LeBlanc et al. 2014). Consistent with a central role for RAGE in HMGB1 trafficking, RAGE deficiency abolishes HMGB1 internalization, whereas genetic deletion of TLR2 or TLR4 does not prevent HMGB1 uptake (Deng et al. 2018; Xu et al. 2014). This perspective develops an idea around the central argument that HMGB1 functions not merely as a soluble cytokine-like mediator, but as a regulated carrier of inflammatory material. Within this model, cholinergic signaling and vagus nerve stimulation act upstream by reducing HMGB1 mobilization and thereby limiting the assembly and uptake of pathogenic HMGB1-containing complexes (Fig. 1A). Vagus nerve stimulation inhibits the inflammatory potential of HMGB1 by preventing its release. A Within the extracellular compartment, HMGB1 forms complexes with many diverse molecular species, as shown here for several examples. These changes in its molecular configuration prevent universal recognition by HMGB1-targeting therapeutic antagonists. One important consequence of vagus nerve stimulation is the inhibition of HMGB1 cellular release via activation of α7nAChR by acetylcholine. As a consequence, VNS prevents the activation of multiple inflammatory pathways by HMGB1. B As one detailed example, HMGB1 associates with damage-associated (DAMPs) and pathogen-associated molecular patterns (PAMPs). These HMGB1–ligand complexes are internalized via RAGE-dependent endocytosis and subsequently trafficked to lysosomes. HMGB1 uniquely disrupts lysosomal membranes, enabling associated danger signals to escape degradation and access the cytosol, where they activate inflammasome pathways and promote inflammation and pain. C Vagus nerve stimulation activates the cholinergic anti-inflammatory pathway which releases acetylcholine, activating the α7nAChR to inhibit these processes by preventing HMGB1 release, as well as limiting RAGE-mediated uptake of HMGB1-containing complexes. This framework highlights using a bioelectronic approach to prevent the activation of multiple inflammatory pathways by reducing HMGB1 cellular release. Figure 1 was created with https://BioRender.com HMGB1 as a carrier of inflammatory cargo A defining feature of extracellular HMGB1 is its ability to bind a broad range of DAMPs and PAMPs (Tang et al. 2023; Ghitti et al. 2025; Bianchi 2009). This property reflects the structural flexibility and positive charge of HMGB1, which favor association with negatively charged ligands such as nucleic acids, microbial products, and other inflammatory mediators. These features of HMGB1 enable it to organize multiprotein or multimolecular complexes that preserve inflammatory cargo in a form competent for cellular delivery. This matters because conventional understanding often places HMGB1 alongside cytokines and chemokines, as though it were simply another extracellular signaling protein. The evidence summarized here supports a more consequential role: HMGB1 can operate as a shuttle that escorts inflammatory material to cells and promotes access of that material to intracellular sensing pathways. In that sense, extracellular HMGB1 is less a passive biomarker of injury than an active determinant of whether danger signals remain extracellular, are degraded after uptake, or reach the cytosol where they trigger inflammasome activation and cell death pathways. A wide spectrum of confirmed HMGB1-associated partners includes DNA (Tian et al. 2007; Yanai et al. 2009; Porat et al. 2018; Liu et al. 2014), RNA (Yanai et al. 2009; Bertheloot et al. 2016), nucleosomes (Urbonaviciute et al. 2008), histones (Pisetsky 2014), interleukin-1 family members (Ferhani et al. 2010; Sha et al. 2008), C1q (Liu et al. 2019), phosphatidylserine (Rouhiainen et al. 2007), lipopolysaccharide (Deng et al. 2018; Youn et al. 2011), lipoteichoic acid (Kwak et al. 2015), hormones (Dulmovits et al. 2022), bacterial toxins (Chang et al. 2024), and viral proteins, including SARS-CoV-2 spike protein (Jung et al. 2025). All of these occupy important roles in physiological and pathophysiological mechanisms of disease. RAGE-mediated uptake and lysosomal escape RAGE-dependent endocytosis is a major mechanism of HMGB1-mediated cellular entry (Deng et al. 2018; Xu et al. 2014; Hu et al. 2025; Alu et al. 2020). HMGB1-containing complexes are internalized through dynamin-dependent pathways and delivered to endolysosomal compartments, where acidic conditions enable HMGB1 to destabilize lysosomal membranes. This step is pivotal because it determines whether inflammatory cargo is degraded or instead escapes into the cytosol to engage intracellular sensors. For example, HMGB1 can bind extracellular lipopolysaccharide (LPS) (Deng et al. 2018; Kim and Kim 2018), promotes its internalization through RAGE, and facilitate lysosomal leakage that allows LPS to reach the cytosol and activate inflammatory molecules (e.g. caspases) that activate inflammation through inflammasome signaling (Fig. 1B). The importance of this mechanism extends beyond endotoxin biology because it establishes a general principle: HMGB1 can govern intracellular accessibility of inflammatory ligands after endocytosis, not merely their extracellular receptor engagement (Porat et al. 2018; Deng et al. 2018; Chang et al. 2024; Liu et al. 2014; Tang et al. 2021; Yang et al. 2016; Andersson et al. 2020). Therefore, HMGB1 delivers danger signals to the intracellular compartments where new signals arise, signals capable of activating potent inflammatory machinery that would otherwise remain insulated from extracellular material. Cholinergic control of HMGB1 accessibility Herein we propose an additional crucial element in this framework: acetylcholine can prevent HMGB1 inflammatory entry by limiting its release (Wang et al. 2003, 2004; Yang et al. 2025; Li et al. 2016; Pavlov et al. 2007) and also by impairing uptake of HMGB1-containing complexes (Yang et al. 2019) (Fig. 1C). During injury or infection, HMGB1 is actively secreted by macrophages, nociceptors, microglia cells, and astrocytes by a mechanism that requires its hyperacetylation and translocation from the nucleus to the cytosol (Bonaldi et al. 2003; Lu et al. 2014; Piovesana et al. 2021). In the presence of acetylcholine, however, signaling through α7nAChR promotes SIRT1-dependent deacetylation, thereby favoring nuclear retention of HMGB1 and reducing its extracellular release (Li et al. 2016). This mechanism provides a direct molecular bridge between acetylcholine released from the vagus nerve or other cells and the availability of an alarmin, HMGB1, capable of driving inflammation and pain. Considering this in the paradigm of the inflammatory reflex, these cholinergic mechanisms, acting independently of the direct cholinergic mechanisms that inhibit cytokine storm, reduce the appearance of HMGB1 in the extracellular compartment and thereby close a major gateway through which inflammatory cargo gains intracellular access (Huston et al. 2007). Ongoing work continues to study the mechanisms by which α7nAChR activation reduces RAGE-mediated endocytosis of HMGB1-containing complexes (Yang et al. 2019). Plausible mechanisms include downregulation of RAGE, inhibition of RAGE transmembrane uptake, and modification of cytoskeletal dynamics. Relevance to pain Nociceptors release HMGB1 in injured and inflamed tissues, where HMGB1 can amplify neuroimmune signaling and sustain peripheral sensitization (Yang et al. 2021; Agalave et al. 2014; Krishna et al. 2025; Maeda et al. 2013). That observation places HMGB1 at a biologically meaningful intersection between immune activation and pain. Inhibiting HMGB1 release from immune cells and nociceptors may therefore influence both inflammatory biomarkers and patient-centered pain outcomes. Both acetylcholine and α7nAChR-specific agonists inhibit neural HMGB1 release by retaining HMGB1 within the nucleus (Yang et al. 2025). Implications for vagus nerve stimulation Vagus nerve stimulation is an FDA approved modality for the treatment of rheumatoid arthritis, epilepsy, depression, and other conditions. Electrical stimulation of the vagus nerve can activate pathways that increase cholinergic signaling, reduce HMGB1 release, and potentially diminish formation and uptake of HMGB1-containing complexes. Since HMGB1 is a late mediator in the host response to injury and infection, interventions that reduce HMGB1 mobilization may therefore remain effective even after disease onset, a point that helps explain the translational appeal of vagus nerve stimulation in inflammatory and pain-related disorders. As vagus nerve stimulation is already an established therapeutic technology in other indications, it offers a practical platform for testing whether control of HMGB1 accessibility improves human disease. The current evidence supports a testable hypothesis in which vagus nerve stimulation acts not only by suppressing inflammatory cytokine production, but also by controlling upstream HMGB1 accessibility. Clinical and conceptual implications Why does this conceptual change concerning the multiple roles of HMGB1 in inflammation matter? Because therapies directed solely at extracellular HMGB1 after its release may fail when HMGB1 is masked within complexes, measured incompletely, or already engaged in cellular delivery pathways. By contrast, interventions that reduce HMGB1 mobilization or block its accessibility may interrupt the process earlier and more effectively. This view also generates practical predictions. First, successful bioelectronic interventions should reduce not only soluble inflammatory mediators but also formation and uptake of HMGB1-containing complexes. Second, early clinical and biomarker studies can be designed to pair vagus nerve stimulation with serial measurement of HMGB1 species and pain outcomes in disorders where both inflammation and symptoms are measurable. Conclusion Reframing HMGB1 through the lens of accessibility rather than abundance provides a coherent explanation for why neutralization strategies may underperform despite strong experimental evidence implicating HMGB1 in disease. HMGB1 can function as a carrier that assembles inflammatory cargo, enters cells through RAGE-dependent pathways, and enables cytosolic access to potent inflammatory machinery. Cholinergic signaling, acting through the inflammatory reflex and the cholinergic anti-inflammatory pathway, can oppose this process by limiting HMGB1 release and reducing uptake of HMGB1-containing complexes. This integrated model creates a direct bridge between basic immunology and bioelectronic medicine. It positions vagus nerve stimulation as an intervention that may restrict inflammatory entry into cells, as well as dampen downstream signaling. Most importantly, it yields a clear and testable clinical proposition: if HMGB1 accessibility is a regulated gateway for inflammation and pain, then clinical studies of vagus nerve stimulation could utilize biomarkers beyond cytokines, by also including changes in HMGB1 mobilization, complex formation, and clinically meaningful pain outcomes. Acknowledgements The authors thank Dr. Kevin J. Tracey for insightful discussions and thoughtful comments that improved the manuscript. Abbreviations High mobility group box 1 protein Alpha7 nicotinic acetylcholine receptors Receptor for advanced glycation end products Toll-like receptor 4 Damage-associated molecular pattern Pathogen-associated molecular pattern Lipopolysaccharide Authors’ contributions All three authors wrote, read and reviewed the manuscript. Funding Research reported in this publication was supported by the Advancing Women in Science and Medicine (AWSM) 2026 Collaboration Award from Northwell Health (Manhasset, NY) (to HY). Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.